IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

Completed · Phase 2 · Has a placebo group

Conditions studied: Sickle Cell Disease, Vaso-occlusive Crisis, Acute Chest Syndrome

In brief

The study will be conducted at 15-20 US centers in a randomized, placebo-controlled, double-blind fashion. Enrollees will be hospitalized sickle cell disease (SCD) patients at-risk for acute chest syndrome (ACS) based on the presence of vaso-occlusive crisis (VOC), fever (T ≥38.0°C) and serum sPLA2 concentration ≥50 ng/mL.

Key facts

Study ID

NCT00434473

Run by

Anthera Pharmaceuticals

People needed

30

Starts

2006-12-01

Expected to finish

2009-12-01

Last updated by the study team

2014-03-04

Who can join

Age: 5 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Howard University Hospital — Washington D.C., District of Columbia, United States
• Children's Healthcare of Atlanta — Atlanta, Georgia, United States
• Children's Memorial Hospital — Chicago, Illinois, United States
• SUNY Downstate Medical Center — Brooklyn, New York, United States
• Duke University Comprehensive Sickle Cell Center — Durham, North Carolina, United States
• Virginia Commonwealth University — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.